Spero Therapeutics, Inc.SPRO
Price (close)
$1.25
Market cap
$72.7M
P/E
9.8x
Revenue (TTM)
$47.0M
Net income
$7.4M
Dividend yield
—
1-year total return
-35.6%
Net margin
15.7%
Revenue growth
-3.3%
Debt / equity
—
What Spero Therapeutics, Inc. does.
No business description on file yet.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $9.3M | $18.3M | $53.5M | $103.8M | $48.0M | $66.8M |
| Net income | -$78.3M | -$89.8M | -$46.4M | $22.8M | -$68.6M | $8.6M |
| Free cash flow | -$86.0M | — | — | — | — | — |
More on SPRO.
- Spero Therapeutics, Inc. summary
- Spero Therapeutics, Inc. financial statements
- Spero Therapeutics, Inc. key metrics
- Spero Therapeutics, Inc. health scores and style box
- Spero Therapeutics, Inc. earnings
- Spero Therapeutics, Inc. dividends
- Spero Therapeutics, Inc. valuation
- Spero Therapeutics, Inc. ownership and insiders
- Spero Therapeutics, Inc. peers
Figures from Spero Therapeutics, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.